<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4096">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03053596</url>
  </required_header>
  <id_info>
    <org_study_id>T127E2</org_study_id>
    <nct_id>NCT03053596</nct_id>
  </id_info>
  <brief_title>LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry)</brief_title>
  <official_title>LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable Hepacellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terumo Europe N.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Terumo Europe N.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this registry is to assess liver toxicity, treatment efficacy, and
      safety of DEB-TACE using anthracyclin loaded LifePearls for treatment of patients with
      unresectable hepatocellular carcinoma allocated to TACE treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma (HCC) is the fifth most common type of cancer in men and the eight
      in women and is the third most common cause of death from cancer worldwide. The overall
      incidence of HCC remains high in developing countries and is steadily rising in most
      industrialized countries.

      Available treatment options depend on the size, number, and location of tumors; degree of
      cirrhosis, if present; and comorbidities; overall performance status; patency of portal
      vein; and presence of metastatic disease. They include surgical (liver resection, liver
      transplantation), medical (e.g. sorafenib…), ablative (ethanol ablation, radiofrequency
      ablation, cryoablation) and intra-arterial (chemoembolization, radioembolization)
      modalities.

      Trans Arterial Chemo-Embolization (TACE) with various drugs (anthracyclines being among the
      most commonly used ones) has been an important therapeutic option for treatment of patients
      with intermediate stage HCC according to BCLC/EORTC guidelines (REF). In order to maximize
      therapeutic efficacy of TACE, chemotherapy loadable beads were developed allowing to lower
      systemic toxicity of chemotherapy, to deliver high and sustained chemotherapy concentration
      to the tumor, and to prolong delivery of drug and embolization to the tumor.

      The purpose of this registry is to evaluate liver and systemic toxicity, treatment efficacy,
      and safety of Drug Elutable Beads -TACE using anthracyclin loaded Life-Pearls -TACE for
      unresectable hepatocellular carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Liver toxicity assessment based on routine CT scans</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver toxicity assessment based on routine blood tests: liver enzymes, phosphatase alkaline, GGT, CBC, bilirubin, albumin. Number of participants with changes in liver function related to TACE treatment.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment efficacy based on response rate assessed by mRECIST criteria</measure>
    <time_frame>3 months after final TACE</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment efficacy based on response rate assessed by RECIST 1.1 criteria</measure>
    <time_frame>3 months after final TACE</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety based on recorded SAE assessed by CTCAE v4.03</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DEB-TACE using anthracyclin loaded LifePearl™</intervention_name>
    <description>The main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of DEB-TACE using anthracyclin loaded LifePearl™ for treatment of patients with unresectable hepatocellular carcinoma allocated to TACE treatment at multidisciplinary tumor board.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with unresectable hepatocellular carcinoma allocated to TACE treatment at
        multidisciplinary tumor board.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients, more than 18 years old, with unresectable hepatocellular carcinoma eligible
             for treatment with anthracyclin loaded LifePearls, allocated to TACE treatment at
             multidisciplinary tumor board and who agree to data collection in the registry by
             signing informed consent form.

        Exclusion Criteria:

          -  This is an observational registry and there are no exclusion criteria apart from
             patient refusal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry de Baere, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Gustave Roussy, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dragica Paunovic, MD</last_name>
    <phone>+32(0)16381311</phone>
    <email>Dragica.Paunovic@terumo-europe.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saskia Cremers</last_name>
    <phone>+32(0)16381389</phone>
    <email>Saskia.Cremers@terumo-europe.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clinchamp</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Noëlle Riquier</last_name>
      <phone>+33 (0)1 40 87 53 58</phone>
      <email>marie-noelle.riquier@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Maxime Ronot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Guiu</last_name>
      <phone>+33 (0)4 67 33 75 40</phone>
      <email>b-guiu@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Boris Guiu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital L'Archet II</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Chevallier</last_name>
      <phone>+33 (0)4 92 03 63 73</phone>
      <email>chevallier.p@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick Chevallier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry de Baere</last_name>
      <phone>+33 (0)1 42 11 54 28</phone>
      <email>Thierry.DEBAERE@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry de Baere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>February 16, 2017</lastchanged_date>
  <firstreceived_date>October 14, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>LifePearl</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
